




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

## Graphical abstract



## Authors

Yaochang Yuan, Xiantao Zhang, Ran Chen, ..., Xin He, Yiwen Zhang, Hui Zhang

## Correspondence

zhangyw57@mail.sysu.edu.cn (Y.Z.), zhangh92@mail.sysu.edu.cn (H.Z.)

## In brief

Yuan et al. construct a bivalent vaccine based on the RBD sequence of two SARS-CoV-2 variants, D614G and B.1.351. Vaccination with a single dose or a prime-boost regimen is protective against SARS-CoV-2 challenge in mice. The bivalent vaccine elicits nAbs against SARS-CoV-2 variants in rhesus macaques with a third-dose regimen

## Highlights

- D614G/B.1.351 bivalent vaccine induces robust immune responses
- Bivalent vaccine protects mice from SARS-CoV-2 infection in a prime-boost manner
- A single dose of bivalent vaccine shows superior protection from B.1.351 infection
- A third-dose strategy elicits nAbs against SARS-CoV-2 variants in rhesus macaques



## Report

# A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

Yaochang Yuan,<sup>1,8</sup> Xiantao Zhang,<sup>1,8</sup> Ran Chen,<sup>1,8</sup> Yuzhuang Li,<sup>1</sup> Bolin Wu,<sup>1</sup> Rong Li,<sup>1</sup> Fan Zou,<sup>2</sup> Xiancai Ma,<sup>1</sup> Xuemei Wang,<sup>1</sup> Qier Chen,<sup>1</sup> Jieyi Deng,<sup>1</sup> Yongli Zhang,<sup>1</sup> Tao Chen,<sup>1</sup> Yingtong Lin,<sup>1</sup> Shumei Yan,<sup>1,3</sup> Xu Zhang,<sup>1</sup> Congrong Li,<sup>4</sup> Xiuqing Bu,<sup>4</sup> Yi Peng,<sup>4</sup> Changwen Ke,<sup>5</sup> Kai Deng,<sup>1,4,6</sup> Ting Pan,<sup>1</sup> Xin He,<sup>1</sup> Yiwen Zhang,<sup>1,\*</sup> and Hui Zhang<sup>1,7,9,\*</sup>

<sup>1</sup>Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

<sup>2</sup>Qianyang Biomedical Research Institute, Guangzhou, Guangdong 510063, China

<sup>3</sup>Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, China

<sup>4</sup>BSL-3 Laboratory, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

<sup>5</sup>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong 511430, China

<sup>6</sup>Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

<sup>7</sup>National Guangzhou Laboratory, Bio-Island, Guangzhou, Guangdong 510320, China

<sup>8</sup>These authors contributed equally

<sup>9</sup>Lead contact

\*Correspondence: zhangyw57@mail.sysu.edu.cn (Y.Z.), zhangh92@mail.sysu.edu.cn (H.Z.)

<https://doi.org/10.1016/j.celrep.2021.110256>

## SUMMARY


Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants.

## INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 245 million people, causing more than 4.9 million deaths worldwide (Wang et al., 2020a; Zhou et al., 2020). Since the outbreak started, various coronavirus disease 2019 (COVID-19) vaccines have been authorized or approved for emergency use, followed by many more at different phases in their development pipelines, including nanoparticle vaccines (Arunachalam et al., 2021; Brouwer et al., 2021; Keech et al., 2020; Ma et al., 2020; Saunders et al., 2021; Walls et al., 2020a). However, the subsequent emergence of SARS-CoV-2 variants, especially those with mutations in the receptor binding domain (RBD) of the spike protein, has caused great concern (Plante et al., 2021; Wang et al., 2021b). The RBD of the spike protein interacts with the major viral receptor angiotensin-converting enzyme 2 (ACE2) to mediate viral entry, and mutations in the RBD cause evasion from neutralizing antibodies (nAbs) or enhanced binding

affinity to ACE2 (Letko et al., 2020; Walls et al., 2020b). Since late 2020, numerous variants have been reported and eventually spread worldwide, notably the B.1.1.7 (alpha, variant of concern [VOC] 202012/01), B.1.351 (known as the beta variant), P.1 (also called gamma), B.1.429, B.1.526, B.1.617.1 (kappa), and B.1.617.2 (delta) lineages, which carry various mutations in the spike (S) region (Figure S4C; Galloway et al., 2021; Hodcroft et al., 2021; Hoffmann et al., 2021; Li et al., 2021b; Resende et al., 2021; Tegally et al., 2020; Zhang et al., 2021b). Importantly, compared with the D614 and D614G lineages, most of these variants, especially those harboring E484K/Q mutants, confer elevated resistance to neutralization from convalescent COVID-19 sera as well as many therapeutic monoclonal antibodies (Garcia-Beltran et al., 2021; Greaney et al., 2021; Hoffmann et al., 2021; Li et al., 2021a, 2021c; Planas et al., 2021; Sun et al., 2021; Wang et al., 2021a; Zhou et al., 2021). Recent clinical studies in South Africa, in parallel, confirmed reduced





**Figure 1. The bivalent D614G/B.1.351\_RBD-NP vaccine elicits a robust immune responses in BALB/c mice and is thermostable and resilient** (A) Schematic of the bivalent D614G/B.1.351\_RBD-NP. The bivalent D614G/B.1.351\_RBD-NP consists of Sd-ferritin, Gv-D614G\_RBD, and Gv-B.1.351\_RBD. The ratio is 50/50 of D614G\_RBD-NP and B.1.351\_RBD-NP in bivalent D614G/B.1.351\_RBD-NP. Sd, SdCatcher; SP, secretory signal peptide; Gv, GvTagOpti. (B) Representative BIACore plots of D614G\_RBD-NP and B.1.351\_RBD-NP bound to hACE2. The  $K_D$  values were calculated by the software BIAevaluation. The  $K_D$  value shown was a mean of three independent experiments. (C and D) D614G\_RBD- and B.1.351\_RBD-specific IgG/IgA titers of immunized BALB/c mice were detected by ELISA. Antibody titers of serum and BALF, which were collected at week 6, were determined by ELISA, and the data are represented as the reciprocal of the endpoint serum dilution.

(legend continued on next page)

efficacy against symptomatic COVID-19 disease for various vaccines based on the original D614/D614G, including the NVX-CoV2373 (Novavax), BNT162b2 (Pfizer-BioNTech), AZD1222 (University of Oxford/AstraZeneca), and Ad26.COV2.S (Janssen/Johnson & Johnson) vaccines (Abu-Raddad et al., 2021; Moyo-Gwete et al., 2021; Shen et al., 2021; Shinde et al., 2021). Some recent studies also show that the protection efficiency of these vaccines against other variants harboring E484K/Q mutations, such as B.1.617.1 harboring L452R/E484Q, is decreased (Cherian et al., 2021; Edara et al., 2021; Kumar et al., 2021). Therefore, strategies for developing updated vaccines against B.1.351 and other variants harboring E484K/Q mutations are urgently needed to avoid potential loss of clinical efficacy. Further, because the magnitude and duration of vaccine protection remains to be determined, an additional boost for the current vaccines could be necessary.

Given that the B.1.351 and P.1 strains harbor K417N/T, E484K, and N501Y mutations in the RBD domain, B.1.526 harbors E484K, and B.1.617.1 harbors L452R and E484Q (Figure S4C), we wanted to develop a D614G- and E484K/Q-specific bivalent vaccine. Because the mutants of B.1.351 exert the highest possibility of immune evasion so far, its RBD was chosen as the representative immunogen for E484K/Q mutant lineages (Diamond et al., 2021; Skelly et al., 2021). To this end, a bivalent D614G/B.1.351 RBD nanoparticle vaccine was developed that comprises a 1:1 mix of D614G\_RBD-NP (D614G RBD nanoparticle vaccine) and B.1.351\_RBD-NP (B.1.351 RBD nanoparticle vaccine). With a prime-boost or single-dose strategy, this bivalent vaccine elicited robust nAbs and full protection against infection with the authentic D614G or B.1.351 strains in human ACE2 (hACE2) transgene mice. Furthermore, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potentially elicited cross-nAbs for SARS-CoV-2 variants in rhesus macaques.

## RESULTS

As described previously, we expressed the ferritin and RBD protein separately and then allow them to covalently conjugate through an isopeptide bond (Ma et al., 2020). To increase conjugation efficiency, we recently developed a GvTagOpti/SdCatcher (Gv/Sd) system derived from *Gardnerella vaginalis* and *Streptococcus dysgalactiae*, respectively. This conjugation system presents immunogen on nanoparticles with much higher efficiency (Zhang et al., 2021c). The Sd-coding sequence was genetically fused at the N terminus of ferritin (Sd-ferritin), whereas the Gv-coding sequence was fused at the N-terminus of the D614G\_RBD or B.1.351\_RBD sequence (Figure 1A). The

purified Gv-D614G\_RBD and Gv-B.1.351\_RBD were irreversibly covalently conjugated to the Sd-ferritin to generate D614G\_RBD-nanoparticle (NP) and B.1.351\_RBD-NP (Figure 1A). The NP conjugates were purified by size exclusion chromatography (SEC) and analyzed by SDS-PAGE (Figures S1A and S1B). Transmission electron microscopy (TEM) of the pooled higher-molecular-weight fractions from SEC revealed well-ordered NPs (Figure S1C). The RBD-conjugated NPs showed spikes protruding from the spherical core after conjugation (Figure S1C). We characterized the antigenicity of NP conjugates by detecting their binding affinity and kinetics with the receptor hACE2 (Ramanathan et al., 2021). The measured binding dissociation constants ( $K_D$ ) of the D614G\_RBD-NP and B.1.351\_RBD-NP with the hACE2 receptor were  $8.67 \times 10^{-9}$  and  $3.23 \times 10^{-9}$  M, respectively, indicating that the epitopes on the NPs are exposed and correctly folded and that the B.1.351\_RBD-NP binds to human ACE2 with increased affinity (Figures 1B and S1D). SEC, TEM, and surface plasmon resonance (SPR) confirmed successful generation of NP vaccines presenting multiple copies of the SARS-CoV-2 RBD proteins.

To evaluate the immunogenicity of these bivalent NP vaccines against the ancestral D614G and B.1.351 variants, BALB/c mice were immunized with these vaccines. We compared two different aluminum adjuvants with the Sigma adjuvant system (SAS) used in our previous study and found that there was no difference in immunogenicity between each group (Figure S1E). Therefore, we chose alhydrogel (InvivoGen) as the adjuvant for this study. BALB/c mice were immunized subcutaneously with 10  $\mu$ g of B.1.351\_RBD-NP or D614G/B.1.351\_RBD-NP adjuvant with alhydrogel in a prime-boost manner. Serum was collected, and mice were euthanized 2 weeks after boost. The B.1.351\_RBD-NP and D614G/B.1.351\_RBD-NP vaccines induced RBD-specific immunoglobulin G (IgG) in serum at approximately  $10^5$  titer and RBD-specific IgA secretion in bronchoalveolar lavage fluid (BALF) specific for the D614G and B.1.351 variants (Figures 1C and 1D). By utilizing pseudovirus neutralization assays, the nAbs induced by D614G/B.1.351\_RBD-NP strongly inhibited D614G and B.1.351 pseudotyped variants (Figure 1E). In line with the previous findings that serum from convalescent COVID-19 individuals showed reduced neutralization against the B.1.351 variant, the D614G\_RBD-NP vaccine showed a reduction of nAbs to the B.1.351 variant in BALB/c mice (Figure 1E; Li et al., 2021c). To study whether these nAbs could inhibit infection with authentic D614G and B.1.351 strains, a focus reduction neutralizing test (FRNT) was conducted (Ma et al., 2020). The nAbs in all NP-vaccinated mice strongly inhibited replication of the authentic D614G and B.1.351 strains. The B.1.351\_RBD-NP vaccine elicited higher neutralization titers against B.1.351 compared with that of D614G,

(E) Groups of serially diluted serum were examined for nAbs against pseudotyped SARS-CoV-2 (D614G/B.1.351). Data represent the 50% neutralizing titers (NT50) of nAbs in each group. Experiments were conducted independently in triplicate.

(F) The nAbs titer of each vaccine group for the authentic SARS-CoV-2 (D614G/B.1.351) was determined by FRNT and is represented as half-maximal inhibitory concentration (IC<sub>50</sub>).

(G and H) Immunoreactivity of bivalent D614G/B.1.351\_RBD-NP for D614G\_RBD and B.1.351\_RBD, determined by ELISA after storage at various temperatures for 2 weeks (G) or after one to five cycles of freezing and thawing (H). Antibody titers of serum collected at week 2 were determined by ELISA, and the data are represented as the reciprocal of the endpoint serum dilution. Each dot represents serum from one animal.

Experiments were conducted independently in triplicate. Data are represented as mean  $\pm$  SD. Adjusted p values were calculated by one-way ANOVA with Tukey's multiple comparisons test. Significant differences between groups linked by horizontal lines are indicated by asterisks. ns, not significant; \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.

whereas the bivalent D614G/B.1.351\_RBD-NP induced a similar robust neutralization response against the authentic D614G and B.1.351 strains, with no significant difference in neutralization titers (Figure 1F). We further determined the cellular immune response of the bivalent NP vaccines. 2 weeks after boost vaccination, splenocytes were obtained, and intracellular cytokine staining (ICCS) was conducted (Figure S2A). All NP-vaccinated mice showed strong polyfunctional CD8<sup>+</sup> T cells expressing interferon  $\gamma$  (IFN- $\gamma$ ) and interleukin-2 (IL-2) and Th1-biased CD4<sup>+</sup> T cells expressing IFN- $\gamma$  (Figure S2B). There was no difference across different groups for Th2-biased IL-4<sup>+</sup>-expressing CD4<sup>+</sup> T cells (Figure S2B).


To determine the stability of NP vaccines, we stored the D614G/B.1.351\_RBD-NP vaccine at  $-80^{\circ}\text{C}$ ,  $-20^{\circ}\text{C}$ ,  $4^{\circ}\text{C}$ , and  $25^{\circ}\text{C}$  for 2 weeks. SDS-PAGE profiles indicated that the protein remained highly stable after 2 weeks of storage at all tested temperatures (Figure S3A), with no loss of immunogenicity in BALB/c mice (Figure 1G). We next assessed the resilience of the D614G/B.1.351\_RBD-NP vaccine by challenging it with multiple rounds of freezing and thawing. Even after five rounds of freezing and thawing, no degradation was observed, based on SDS-PAGE analysis (Figure S3B), and no loss of immunogenicity in BALB/c mice (Figure 1H). The B.1.351\_RBD-NP vaccine and the bivalent D614G/B.1.351\_RBD-NP vaccine induced robust humoral and cellular immune responses with a high level of stability.

To determine bivalent D614G/B.1.351\_RBD-NP vaccine protection against D614G and B.1.351 variant infection, we immunized transgenic hACE2 mice, which expressed humanized ACE2, with NP vaccines (Figure 2A). The RBD-specific IgG against the D614G and B.1.351 strains was quite high in all NP-immunized hACE2 mice 2 weeks after boost (Figure 2B). In the 50% focus reduction neutralizing test (FRNT50) assay, the D614G/B.1.351\_RBD-NP vaccine elicited a similar robust neutralization response against the authentic D614G and B.1.351 strains, whereas a 9-fold decrease of neutralization against the B.1.351 strain was observed in D614G\_RBD-NP-immunized hACE2 mice (Figure 2C). All immunized hACE2 mice were challenged intranasally with  $4 \times 10^4$  plaque-forming units (PFUs) of the D614G or B.1.351 strains, respectively, and euthanized 5 days after challenge. The SARS-CoV-2 viral RNA copies in the lungs and trachea were used to quantify virus replication. Control hACE2 mice had an average of  $5.84 \times 10^5$  and  $6.10 \times 10^4$  copies/mL for D614G and  $6.75 \times 10^5$  and  $2.69 \times 10^5$  copies/mL for the B.1.351 strain in the lungs and trachea, respectively, whereas D614G/B.1.351\_RBD-NP-immunized hACE2 mice had undetectable levels of viral RNA (Figures 2D and 2E). The D614G\_NP vaccine remained overall efficacious and delivered notable cross-protection against the B.1.351 variant (Figure 2E). Moreover, the SARS-CoV-2 nucleocapsid (N) antigen was undetectable in the lung tissue of all NP-vaccinated hACE2 mice but was detected in control mice (Figures 2F–2I). Hematoxylin and eosin (H&E) staining of lung tissue showed a reduction of inflammation in immunized hACE2 mice compared with control mice (Figures 2F–2I).

In our previous study, we reported that a significant amount of nAbs had been induced by our NP vaccines 4 weeks after priming but before boost vaccination, indicating that single-dose vaccination could be enough to elicit sufficient nAbs against

SARS-CoV-2 (Ma et al., 2020). Here we evaluate the immunogenicity and *in vivo* protection ability of a single dose of the bivalent D614G/B.1.351\_RBD-NP vaccine (Figure 3A). Five hACE2 mice were immunized with 10  $\mu\text{g}$  of the D614G/B.1.351\_RBD-NP vaccine or an equimolar amount of D614G/B.1.351\_RBD-monomer as a control. Because the prime-boost strategy of the NP vaccine has been carefully evaluated using a monomer as a control in our previous study, here we also set the D614G/B.1.351\_RBD-monomer group as a control for the single-dose strategy (Ma et al., 2020). Serum was collected 6 weeks after vaccination (Figure 3A). RBD-specific IgG against the D614G and B.1.351 strains was detectable in all NP-immunized hACE2 mice (Figure 3B). With the FRNT50 assay and pseudovirus neutralization assays, a single dose of the D614G/B.1.351\_RBD-NP vaccine induced significantly higher neutralization titers against the pseudovirus and authentic D614G and B.1.351 variants compared with D614G/B.1.351\_RBD-monomer (Figures 3C, 3D and, S4A). All immunized hACE2 mice were challenged intranasally with  $4 \times 10^4$  PFUs of the D614G or B.1.351 strains, respectively, and euthanized 5 days after challenge. Although the single dose of D614G/B.1.351\_RBD-monomer had an average of  $1.62 \times 10^5$  and  $3.88 \times 10^4$  copies/mL for the D614G strain and  $1.54 \times 10^5$  and  $3.17 \times 10^4$  copies/mL for the B.1.351 strain in the lungs and trachea, respectively, all single-dose D614G/B.1.351\_RBD-NP-immunized hACE2 mice had undetectable levels of viral RNA (Figures 3E and 3F). The lungs were analyzed for histopathology and immunohistochemistry. Histopathology examination indicated severe bronchopneumonia and interstitial pneumonia in the D614G/B.1.351\_RBD-monomer group, with edema and bronchial epithelial cell desquamation and infiltration of lymphocytes within alveolar spaces. In contrast, only very mild bronchopneumonia was observed in the D614G/B.1.351\_RBD-NP vaccine group (Figures 3G and 3H). Similarly, immunohistochemistry assays detected the SARS-CoV-2 N antigen in the D614G/B.1.351\_RBD-monomer group, but the SARS-CoV-2 N antigen was undetectable in lung tissue of the single-dose-immunized D614G/B.1.351\_RBD-NP group (Figures 3I and 3J). These data demonstrated that single-dose vaccination of the D614G/B.1.351\_RBD-NP vaccine caused significant prevention of replication of the authentic D614G and B.1.351 strains in the lungs.

Further, we compared the protection efficiency of the bivalent vaccine strategy and the original D614G\_RBD-NP vaccine from the B.1.351 strain. hACE2 mice were immunized with 2  $\mu\text{g}$ , 5  $\mu\text{g}$ , and 10  $\mu\text{g}$  of the bivalent vaccine and D614G\_RBD-NP vaccine in a single-dose regimen. Six weeks after vaccination, serum RBD-specific IgG titers against the B.1.351 strain were roughly comparable for the two groups at three different doses (Figure S4B). In the FRNT50 assay, the D614G/B.1.351\_RBD-NP vaccine produced higher nAb responses against the authentic B.1.351 strain in mice vaccinated with a dose of 5  $\mu\text{g}$  and 10  $\mu\text{g}$  (Figure 3K). All immunized hACE2 mice were challenged intranasally with  $4 \times 10^4$  PFUs of the B.1.351 strain and euthanized 5 days after challenge. Compared with the D614G\_RBD-NP vaccine group, the bivalent D614G/B.1.351\_RBD-NP vaccine showed better protection, as demonstrated by lower levels of viral RNA in the lungs and a reduction of inflammation, as seen by histopathological examination of lung tissue (Figure 3L and 3M).



**Figure 2. The bivalent D614G/B.1.351\_RBD-NP vaccine protects against D614G and (B)1.351 variant infection in hACE2 mice**

(A) Schematic of hACE2 mouse vaccination. Five mice in each group were primer-boost-vaccinated with the bivalent D614G/B.1.351\_RBD-NP on day 0 and day 28. Mice were challenged with authentic SARS-CoV-2 (D614G/B.1.351) on day 56. All mice were bled and euthanized 5 days after challenge.


(B) D614G\_RBD-specific and B.1.351\_RBD-specific IgG antibody titers of serum were determined using ELISA by serial dilution and are represented as the reciprocal of the endpoint serum dilution.

(C) The serum of each mouse was 10-fold serially diluted and incubated with 500 focus-forming units (ffu) of authentic SARS-CoV-2 (D614G/B.1.351), followed by incubation with Vero E6 cells. The FRNT spots of each well were counted. FRNT50 of nAbs of each vaccine group was determined by FRNT and is represented as IC<sub>50</sub>. (D and E) Viral RNA copies in the lungs and trachea of each mouse were determined by qRT-PCR and plotted as log<sub>10</sub> copies per milliliter. A dotted line indicates the limit of detection (LOD).

(F and G) H&E staining of the lungs of each mouse.

(H and I) Immunohistochemistry (IHC) against N proteins was evaluated in the lungs of each mouse. Scale bars (F–I) represent 50 μm. Each dot represents serum from one animal.

Experiments were conducted independently in triplicate. Data are represented as mean ± SD. Adjusted p values were calculated by one-way ANOVA with Tukey's multiple comparisons test. Significant differences between groups linked by horizontal lines are indicated by asterisks. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.



(legend on next page)



These data demonstrated the superiority and necessity of the bivalent vaccine strategy, particularly in a single-dose regimen.

Finally, we assess the cross-protection of the updated bivalent D614G/B.1.351\_RBD-NP vaccine as a third dose on previously immunized rhesus macaques (Wu et al., 2021). Rhesus macaques were immunized with 50  $\mu$ g of the D614G\_RBD-NP vaccine on days 1 and 28, and the robustness of the nAbs against the authentic D614G and B.1.351 strains was monitored over the course of more than 8 months (Figure 4A; Ma et al., 2020). As measured by FRNT50 assay against the D614G authentic virus, nAb titers in serum from immunized rhesus macaques were elicited 14 days after priming by the D614G\_RBD-NP vaccine and peaked following another 14 days after the first boost. The nAb titers thereafter remained significant but eventually waned over a course of 8 months. Interestingly, serum from immunized animals showed consistently higher nAb titers against the D614G strain than the B.1.351 strain (Figure 4B).

To evaluate the ability of the bivalent D614G/B.1.351\_RBD-NP vaccine to boost pre-existing immunity and increase neutralization of the D614G and B.1.351 strains, a third dose of 50  $\mu$ g of the bivalent D614G/B.1.351\_RBD-NP vaccine was administered on day 282 (Figure 4A). The RBD-specific IgG titers against the D614G and B.1.351 strains were quite high after a third dose of the vaccine, reaching approximately  $10^5$  titers (Figure S4D). Following the bivalent D614G/B.1.351\_RBD-NP vaccine booster injection, the nAb titers against the authentic D614G virus increased significantly, exceeding the previously measured peak for the D614G\_RBD-NP level. The third dose of the D614G/B.1.351\_RBD-NP vaccine increased the neutralization titers against the D614G and B.1.351 strains 15-fold and 65-fold, respectively (Figures 4B and S4E). Then we determined whether the D614G/B.1.351\_RBD-NP vaccine booster elicited nAbs against other SARS-CoV-2 variants. 4 weeks after the third dose of the D614G/B.1.351\_RBD-NP vaccine, the rhesus macaque sera potentially neutralized the pseudotyped viruses of current major SARS-CoV-2 variants, including B.1.1.7, B.1.351, P.1, B.1.429, B.1.526, and B.1.617.1 (Figure 4C). Fifteen convalescent sera, which were collected in Guangzhou and Zhuhai in

South China before April 15, 2020 and therefore excluded existence of the epidemic variants of SARS-CoV-2 except for the D614 and D614G strains, were used as controls for the pseudovirus neutralizing assay against SARS-CoV-2 variants (Figure S4F; Liu et al., 2020). The convalescent sera were 10-fold less effective at neutralizing B.1.351 and 23-fold less effective for B.1.617.1 in comparison with its neutralization of the D614G strain (Figure S4F). Similarly, the sera from rhesus macaques on day 282 (before the third dose) showed a significant reduction of neutralizing capacity of the B.1.351 and P.1 strains and especially the B.1.617.1 strain. Interestingly, the third dose of D614G/B.1.351\_RBD-NP immunization for rhesus macaques potentially elicited nAbs against all viral variants we tested (Figure 4C). This new boost especially enhances the nAb titer for B.1.617.1 33-fold, which is still slightly lower than that of the D614G strain (Figure 4C).


## DISCUSSION

In this study, we developed a bivalent D614G/B.1.351\_RBD-NP vaccine to prevent infection with the early strain and viral variants harboring E484K/Q mutants. The nAbs induced by this bivalent vaccine are quite high, and the protection from the authentic D614G and B.1.351 strains in hACE2 mice is complete. Protection not only occurs with the initial prime-boost strategy but also with the initial single-dose strategy. Therefore, this bivalent NP vaccine could be used for initial prime-boost or single-dose vaccination for those who never received any COVID-19 vaccine. In addition, we proposed a third-dose (second booster) strategy, which is particularly important given the accelerating rollout of global vaccination (Kreier, 2021). Notably, with the single-dose strategy, a robust immune response against B.1.351 viruses depends on at least a 5- $\mu$ g dose in our experiment settings. This result suggests that a certain amount of vaccine is required for initiating the immune response. In rhesus macaques receiving initial prime-boost inoculation of the D614G-specific NP vaccine, the nAbs for the D614G and viral variants eventually decreased. A third-dose inoculation with a bivalent NP vaccine significantly boosted the nAb titers against the D614G and

### Figure 3. Protection efficacy of a single dose of the bivalent D614G/B.1.351\_RBD-NP vaccine against D614G and (B)1.351 variant infection in hACE2 mice

- (A) Schematic of hACE2 mouse vaccination. Five mice in each group were vaccinated with a single dose of the bivalent D614G/B.1.351\_RBD-NP on day 0. Mice were challenged with authentic SARS-CoV-2 on day 42. All mice were bled and euthanized 5 days after challenge.
- (B) D614G\_RBD-specific and B1.351\_RBD-specific IgG antibody titers of serum were determined using ELISA by serial dilution and are represented as the reciprocal of the endpoint serum dilution.
- (C) The nAbs titer for SARS-CoV-2 pseudovirus (D614G/B.1.351) of vaccinated hACE2 mice by pseudotyped virus neutralization assay, represented as  $IC_{50}$ .
- (D) The serum of each mouse was 10-fold serially diluted and incubated with 500 ffu of authentic SARS-CoV-2 (D614G/B.1.351), followed by incubation with Vero E6 cells. The FRNT spots of each well were counted. FRNT50 of nAbs of each vaccine group was determined by FRNT and is represented as  $IC_{50}$ .
- (E and F) Viral RNA copies in the lungs and trachea of each mouse were determined by qRT-PCR and plotted as  $\log_{10}$  copies per milliliter. A dotted line indicates the LOD.
- (G and H) H&E staining in the lungs of each mouse.
- (I and J) IHC against N proteins was evaluated in the lungs of each mouse.
- (K) The serum of each mouse was 10-fold serially diluted and incubated with 500 ffu of the authentic B.1.351 strain, followed by incubation with Vero E6 cells. The FRNT spots of each well were counted. FRNT50 of nAbs of each vaccine group was determined by FRNT and is represented as  $IC_{50}$ .
- (L) Viral RNA copies in the lungs of each mouse were determined by qRT-PCR and plotted as  $\log_{10}$  copies per milliliter. A dotted line indicates the LOD.
- (M) H&E staining in the lungs of each mouse.

Scale bars in (G)–(J) and (M) represent 50  $\mu$ m. Each dot represents serum from one animal. Experiments were conducted independently in triplicate. Data are represented as mean  $\pm$  SD. Adjusted p values were calculated by one-way ANOVA with Tukey's multiple comparisons test. Significant differences between groups linked by horizontal lines are indicated by asterisks. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .



**Figure 4. A third dose of the bivalent D614G/B.1.351\_RBD-NP vaccine in rhesus macaques previously vaccinated with two doses of D614G\_RBD-NP induces cross-neutralization of viral variants**

(A) Schematic of rhesus macaque vaccination. Four rhesus macaques were first vaccinated with primer-boost D614G\_RBD-NP on day 0 and day 28 and then vaccinated with bivalent D614G/B.1.351\_RBD-NP on day 282. Serum was collected at the indicated times.

(B) The serum of each rhesus macaque at different times was 10-fold serially diluted and incubated with 500 ffu of authentic SARS-CoV-2 (D614G/B.1.351), followed by incubation with Vero E6 cells. The FRNT spots of each well were counted. FRNT50 of nAbs of authentic SARS-CoV-2 (D614G/B.1.351) was determined by FRNT and plotted as a time-course curve.

(C) The nAbs titer for the SARS-CoV-2 pseudovirus (D614G/D614/B.1.1.7/B.1.351/P.1/B.1.429/B.1.526/B.1.617.1) of rhesus macaques before and after the third boost with D614G/B.1.351\_RBD-NP was determined by pseudotyped virus neutralization assay and is represented as IC<sub>50</sub>. Each dot represents serum from one animal.

Experiments were conducted independently in triplicates. Data are represented as mean ± SD. Adjusted p values were calculated by one-way ANOVA with Tukey's multiple comparisons test. Significant differences between groups linked by horizontal lines are indicated by asterisks. \*p < 0.05, \*\*p < 0.01.

B.1.351 strains at almost the same level. Notably, the deterioration rate of the D614G nAb titer is slower after the third dose compared with that after the second dose, suggesting involvement of a stronger memory immune response. Importantly, the third dose of immunization with the bivalent NP vaccine also potentially elicited nAbs against almost all variants we tested, albeit with a slight deficiency for B.1.617.1.

A recent work indicates that a NP vaccine based on an early strain is enough to fully protect an animal from infection with viral variants, including B.1.351 (Saunders et al., 2021). Although our data support this claim, we show that, after initial prime-boost with the NP vaccine targeting D614G, the nAb titers for the D614G strain will eventually decrease, and the decrease of nAb titers for B.1.351 is even more significant. This causes concern regarding the long persistence of immunity against viral variants after NP vaccine administration targeting the early strain. Given that SARS-CoV-2 variants with the E484K/Q

mutant dominate in many regions of the world and that the bivalent vaccine has a potent capability to boost nAb titers against viral variants, we suggest that it is necessary to develop a bivalent NP vaccine targeting the early strain and B.1.351 strain, which could be sufficient for the current COVID-19 pandemic with the threat of 484K/Q mutants. Given that SARS-CoV-2 exhibits a significant capability to evolve after an almost 2-year epidemic, a vaccine for SARS-CoV-2 variants could be developed.

To deal with the pandemic caused by SARS-CoV-2 variants, in addition to updating the design of immunogen, the inoculation strategy should also be optimized (Huang et al., 2021b; Powell et al., 2021; Yahalom-Ronen et al., 2020). Because the bivalent NP vaccine has potent protection efficiency in hACE2 mice with a single dose and is stable at ambient temperature and resistant to freezing and thawing with minimal loss of immunogenicity, long-distance distribution of this bivalent NP vaccine

could become quite easy, especially to countries where cold-chain resources are incomplete.

### Limitations of the study

Our study has potential limitations. Only the D614G/B.1.351\_RBD-NP vaccine was evaluated as a third dose. The ability of D614G\_RBD-NP or B.1.351\_RBD-NP to boost immunity against the D614G and B.1.351 strains has not yet been assessed, although cross-protecting nAbs against the viral variants are expected because of the high levels of titers.

### STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Ethics statements
  - Cells and viruses
  - Animal models
- METHOD DETAILS
  - Protein expression and purification
  - Surface plasmon resonance (SPR)
  - Size-exclusion chromatography (SEC)
  - Transmission electron microscopy (TEM)
  - Animal vaccination
  - Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
  - Enzyme linked immunosorbent assay (ELISA)
  - SARS-CoV-2 infection
  - Histopathology and immunohistochemistry
  - Focus reduction neutralizing test (FRNT)
  - Pseudotyped virus neutralization assay
  - Intracellular cytokine staining (ICCS)
- QUANTIFICATION AND STATISTICAL ANALYSIS

### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2021.110256>.

### ACKNOWLEDGMENTS

This work was supported by the Special 2019-nCoV Project of the National Key Research and Development Program of China (2020YFC0841400), the Emergency Key Program of Guangzhou Laboratory (EKPG21-24), the Special 2019-nCoV Program of the Natural Science Foundation of China (NSFC; 82041002), the Special Research and Development Program of Guangzhou (202008070010), and the Important Key Program of the NSFC (81730060) (to H.Z.). This work was also supported by National Natural Science Foundation of China (32000613) and the Guangdong Basic and Applied Basic Research Foundation (2019A1515010882) (to Yiwen Zhang) and the Guangzhou Basic and Applied Basic Research Foundation (202102021094) (to Xu Zhang).

### AUTHOR CONTRIBUTIONS

Conceptualization, Y.Y., Yiwen Zhang, and H.Z.; methodology, Y.Y., Xiantao Zhang, R.C., Yiwen Zhang, and H.Z.; investigation, Y.Y., Xiantao Zhang, R.C., Y. Li, B.W., R.L., X.W., Q.C., J.D., Yongli Zhang, T.C., F.Z., Y. Lin, S.Y., X.M., Xu Zhang, C.L., X.B., Y.P., K.D., T.P., X.H., Yiwen Zhang, and H.Z.; writing – original draft, Y.Y., Xiantao Zhang, R.C., Yiwen Zhang, and H.Z.; writing – review & editing, Y.Y., Xiantao Zhang, R.C., Yiwen Zhang, and H.Z.; funding acquisition, Yiwen Zhang and H.Z.; resources, R.C., F.Z., C.K., K.D., T.P., X.H., Yiwen Zhang, and H.Z.; supervision, H.Z.

### DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: May 27, 2021

Revised: July 26, 2021

Accepted: December 21, 2021

Published: December 23, 2021

### REFERENCES

- Abu-Raddad, L.J., Chemaitelly, H., Butt, A.A., and National Study Group for, C.-V. (2021). Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. *N. Engl. J. Med.* 385, 187–189. <https://doi.org/10.1056/NEJMc2104974>.
- Arunachalam, P.S., Walls, A.C., Golden, N., Atyeo, C., Fischinger, S., Li, C., Aye, P., Navarro, M.J., Lai, L., Edara, V.V., et al. (2021). Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. *Nature* 594, 253–258. <https://doi.org/10.1038/s41586-021-03530-2>.
- Brouwer, P.J.M., Brinkkemper, M., Maisonnasse, P., Dereuddre-Bosquet, N., Grobden, M., Claireaux, M., de Gast, M., Marlin, R., Chesnais, V., Diry, S., et al. (2021). Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. *Cell* 184, 1188–1200.e1119. <https://doi.org/10.1016/j.cell.2021.01.035>.
- Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., and Panda, S. (2021). Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. *bioRxiv*. <https://doi.org/10.1101/2021.04.22.440932>.
- Diamond, M., Chen, R., Xie, X., Case, J., Zhang, X., VanBlargan, L., Liu, Y., Liu, J., Errico, J., and Winkler, E. (2021). SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. *Res. Sq.* <https://doi.org/10.21203/rs.3.rs-228079/v1>.
- Edara, V.-V., Lai, L., Sahoo, M., Floyd, K., Sibai, M., Solis, D., Flowers, M.W., Hussaini, L., Ciric, C.R., and Bechnack, S. (2021). Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. *bioRxiv*. <https://doi.org/10.1101/2021.05.09.443299>.
- Galloway, S.E., Paul, P., MacCannell, D.R., Johansson, M.A., Brooks, J.T., MacNeil, A., Slayton, R.B., Tong, S.X., Silk, B.J., Armstrong, G.L., et al. (2021). Emergence of SARS-CoV-2 B.1.1.7 lineage - United States, december 29, 2020-january 12, 2021. *Mmwr-Morbidity Mortality Weekly Rep.* 70, 95–99.
- Garcia-Beltran, W.F., Lam, E.C., Denis, K.S., Nitido, A.D., Garcia, Z.H., Hauser, B.M., Feldman, J., Pavlovic, M.N., Gregory, D.J., and Poznansky, M.C. (2021). Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell* 184, 2372–2383.e9.
- Greaney, A.J., Loes, A.N., Crawford, K.H.D., Starr, T.N., Malone, K.D., Chu, H.Y., and Bloom, J.D. (2021). Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe*. 29, 463–476.e6. <https://doi.org/10.1016/j.chom.2021.02.003>.
- Hodcroft, E.B., Domman, D.B., Snyder, D.J., Oguntuyo, K., Van Diest, M., Densmore, K.H., Schwalm, K.C., Femling, J., Carroll, J.L., Scott, R.S., et al. (2021). Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike

- protein variants affecting amino acid position 677. medRxiv. <https://doi.org/10.1101/2021.02.12.21251658>.
- Hoffmann, M., Arora, P., Gross, R., Seidel, A., Hornich, B.F., Hahn, A.S., Kruger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021). SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. *Cell* **184**, 2384–2393.e12. <https://doi.org/10.1016/j.cell.2021.03.036>.
- Huang, B., Dai, L., Wang, H., Hu, Z., Yang, X., Tan, W., and Gao, G.F. (2021a). Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv. <https://doi.org/10.1101/2021.02.01.429069>.
- Huang, Q., Ji, K., Tian, S., Wang, F., Huang, B., Tong, Z., Tan, S., Hao, J., Wang, Q., Tan, W., et al. (2021b). A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. *Nat. Commun.* **12**, 776. <https://doi.org/10.1038/s41467-021-21037-2>.
- Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J.S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020). Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *N. Engl. J. Med.* **383**, 2320–2332. <https://doi.org/10.1056/NEJMoa2026920>.
- Kreier, F. (2021). 'Unprecedented achievement': who received the first billion COVID vaccinations? *Nature*. <https://doi.org/10.1038/d41586-021-01136-2>.
- Kumar, V., Singh, J., Hasnain, S.E., and Sundar, D. (2021). Possible link between higher transmissibility of B. 1.617 and B. 1.1. 7 variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity. bioRxiv. <https://doi.org/10.1101/2021.04.29.441933>.
- Letko, M., Marzi, A., and Munster, V. (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat. Microbiol.* **5**, 562–569. <https://doi.org/10.1038/s41564-020-0688-y>.
- Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., et al. (2021a). SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. *Cell* **184**, 2362–2371.e9. <https://doi.org/10.1016/j.cell.2021.02.042>.
- Li, R., Liu, J., and Zhang, H. (2021b). The challenge of emerging SARS-CoV-2 mutants to vaccine development. *J. Genet. Genomics* **48**, 102–106. <https://doi.org/10.1016/j.jgg.2021.03.001>.
- Li, R., Ma, X., Deng, J., Chen, Q., Liu, W., Peng, Z., Qiao, Y., Lin, Y., He, X., and Zhang, H. (2021c). Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques. *Cell Mol Immunol.* **18**, 1058–1060. <https://doi.org/10.1038/s41423-021-00641-8>.
- Liu, B., Shi, Y., Zhang, W., Li, R., He, Z., Yang, X., Pan, Y., Deng, X., Tan, M., Zhao, L., et al. (2020). Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies. *Cell Mol Immunol* **17**, 1098–1100. <https://doi.org/10.1038/s41423-020-00528-0>.
- Ma, X., Zou, F., Yu, F., Li, R., Yuan, Y., Zhang, Y., Zhang, X., Deng, J., Chen, T., Song, Z., et al. (2020). Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. *Immunity* **53**, 1315–1330.e19. <https://doi.org/10.1016/j.immuni.2020.11.015>.
- Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B.E., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021). Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351). *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMc2104192>.
- Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M.M., Bishop, E., et al. (2021). Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nat. Med.*, 1–8. <https://doi.org/10.1038/s41591-021-01318-5>.
- Plante, J.A., Mitchell, B.M., Plante, K.S., Debink, K., Weaver, S.C., and Menachery, V.D. (2021). The variant gambit: COVID-19's next move. *Cell Host Microbe*. **29**, 508–515. <https://doi.org/10.1016/j.chom.2021.02.020>.
- Powell, A.E., Zhang, K., Sanyal, M., Tang, S., Weidenbacher, P.A., Li, S., Pham, T.D., Pak, J.E., Chiu, W., and Kim, P.S. (2021). A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. *ACS Cent. Sci.* **7**, 183–199. <https://doi.org/10.1021/acscentsci.0c01405>.
- Ramanathan, M., Ferguson, I., Miao, W., and Khavari, P. (2021). SARS-CoV-2 B. 1.1. 7 and B. 1.351 Spike variants bind human ACE2 with increased affinity. bioRxiv. [https://doi.org/10.1016/S1473-3099\(21\)00262-0](https://doi.org/10.1016/S1473-3099(21)00262-0).
- Resende, P.C., Bezerra, J.F., Vasconcelos, R., Arantes, I., Appolinario, L., Mendonça, A.C., Paixao, A.C., Rodrigues, A.C.D., Silva, T., and Rocha, A.S. (2021). Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020. *Virological* **10**.
- Saunders, K.O., Lee, E., Parks, R., Martinez, D.R., Li, D., Chen, H., Edwards, R.J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021). Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. *Nature* **594**, 553–559. <https://doi.org/10.1038/s41586-021-03594-0>.
- Shen, X., Tang, H., Pajon, R., Smith, G., Glenn, G.M., Shi, W., Korber, B., and Montefiori, D.C. (2021). Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351. *N. Engl. J. Med.* **384**, 2352–2354. <https://doi.org/10.1056/NEJMc2103740>.
- Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M.S.L., Moodley, D., Hanley, S., et al. (2021). Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. *N. Engl. J. Med.* **384**, 1899–1909. <https://doi.org/10.1056/NEJMoa2103055>.
- Skelly, D.T., Harding, A.C., Gilbert-Jaramillo, J., Knight, M.L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., and Team, M.L. (2021). Vaccine-Induced Immunity Provides More Robust Heterotypic Immunity than Natural Infection to Emerging SARS-CoV-2 Variants of Concern. <https://doi.org/10.21203/rs.3.rs-226857/v1>.
- Sun, D., Sang, Z., Kim, Y.J., Xiang, Y., Cohen, T., Belford, A.K., Huet, A., Conway, J.F., Sun, J., Taylor, D.J., et al. (2021). Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes. bioRxiv. <https://doi.org/10.1101/2021.03.09.434592>.
- Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E.J., and Msomi, N. (2020). Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. <https://doi.org/10.1101/2020.12.21.20248640>.
- Walls, A.C., Fiala, B., Schafer, A., Wrenn, S., Pham, M.N., Murphy, M., Tse, L.V., Shehata, L., O'Connor, M.A., Chen, C., et al. (2020a). Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. *Cell* **183**, 1367–1382.e1317. <https://doi.org/10.1016/j.cell.2020.10.043>.
- Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020b). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **181**, 281–292.e86. <https://doi.org/10.1016/j.cell.2020.02.058>.
- Wang, C., Horby, P.W., Hayden, F.G., and Gao, G.F. (2020a). A novel coronavirus outbreak of global health concern. *Lancet* **395**, 470–473. [https://doi.org/10.1016/S0140-6736\(20\)30185-9](https://doi.org/10.1016/S0140-6736(20)30185-9).
- Wang, W., Zhou, X., Bian, Y., Wang, S., Chai, Q., Guo, Z., Wang, Z., Zhu, P., Peng, H., Yan, X., et al. (2020b). Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. *Nat. Nanotechnol.* **15**, 406–416. <https://doi.org/10.1038/s41565-020-0648-y>.
- Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P.D., et al. (2021a). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* **593**, 130–135. <https://doi.org/10.1038/s41586-021-03398-2>.
- Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021b). Spike mutations in SARS-CoV-2 variants confer resistance to antibody neutralization. bioRxiv. <https://doi.org/10.1101/2021.03.09.434497>.
- Wu, K., Choi, A., Koch, M., Elbashir, S., Ma, L., Lee, D., Woods, A., Henry, C., Palandjian, C., and Hill, A. (2021). Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. bioRxiv. <https://doi.org/10.1101/2021.04.13.439482>.

Yahalom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E.B., Israeli, O., Milrot, E., Stein, D., et al. (2020). A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge. *Nat. Commun.* *11*, 6402. <https://doi.org/10.1038/s41467-020-20228-7>.

Zhang, J.S., Huang, F., Xia, B.J., Yuan, Y.C., Yu, F., Wang, G.W., Chen, Q.Y., Wang, Q., Li, Y.Z., Li, R., et al. (2021a). The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry. *Signal. Transduction Targeted Ther.* *6*, 1–11. <https://doi.org/10.1038/s41392-021-00604-5>.

Zhang, W., Davis, B.D., Chen, S.S., Sincuir Martinez, J.M., Plummer, J.T., and Vail, E. (2021b). Emergence of a novel SARS-CoV-2 variant in southern California. *JAMA* *325*, 1324–1326. <https://doi.org/10.1001/jama.2021.1612>.

Zhang, X., Yuan, Y., Wu, B., Wang, X., Lin, Y., Luo, Y., Li, R., Chen, T., Deng, J., Zhang, X., et al. (2021c). Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles. *Cell Mol. Immunol.* *18*, 2042–2044. <https://doi.org/10.1038/s41423-021-00736-2>.

Zhang, Y., Chen, Y., Li, Y., Huang, F., Luo, B., Yuan, Y., Xia, B., Ma, X., Yang, T., Yu, F., et al. (2021d). The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Iota. *Proc. Natl. Acad. Sci. U S A* *118*, e2024202118. <https://doi.org/10.1073/pnas.2024202118>.

Zhang, Y., Hu, H., Liu, W., Yan, S.M., Li, Y., Tan, L., Chen, Y., Liu, J., Peng, Z., Yuan, Y., et al. (2021e). Amino acids and RagD potentiate mTORC1 activation in CD8(+) T cells to confer antitumor immunity. *J. Immunother. Cancer* *9*, e002137. <https://doi.org/10.1136/jitc-2020-002137>.

Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., et al. (2021). Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* *184*, 2348–2361.e2346. <https://doi.org/10.1016/j.cell.2021.02.037>.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* *579*, 270–273. <https://doi.org/10.1038/s41586-020-2012-7>.

## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP	Invitrogen	Cat#31430; RRID: AB_228307
Goat anti-Monkey IgG (H+L) Secondary Antibody, HRP	Invitrogen	Cat#PA1-84631; RRID: AB_933605
HRP*Polyclonal Goat Anti Mouse IgA	Immunoway	Cat#RS030211
Rabbit Polyclonal anti-SARS-CoV-2 Nucleoprotein (N) Antibody	Sino Biological	Cat#40143-T62; RRID: AB_2892769
Goat Anti-Rabbit IgG Secondary Antibody (HRP)	Sino Biological	Cat#SSA004
Ultra-LEAF Purified anti-mouse CD28 Antibody	Biolegend	Cat#102116; RRID: AB_11147170
CD3e Monoclonal Antibody (145-2C11), PE-Cyanine7	eBioscience	Cat#25-0031-82; RRID: AB_469572
Alexa Fluor 700 anti-mouse CD4 Antibody	Biolegend	Cat#100429; RRID: AB_493698
CD8a Monoclonal Antibody (53-6.7), FITC	eBioscience	Cat# 11-0081-86; RRID: AB_464917
APC anti-mouse IFN- $\gamma$ Antibody	Biolegend	Cat#505810; RRID: AB_315404
PerCP/Cyanine5.5 anti-mouse IL-2 Antibody	Biolegend	Cat#503822; RRID: AB_2123676
PE anti-mouse IL-4 Antibody	Biolegend	Cat#504103; RRID: AB_315317
<b>Bacterial and virus strains</b>		
<i>E. coli</i> BL21	Takara	Cat#9126
SARS-CoV-2 (D614G)	This paper	hCoV-19/CHN/SYSU-IHV/2020 (D614G); GISAID: EPI_ISL_444969
SARS-CoV-2 (B.1.351)	Guangdong Provincial Center for Disease Control and Prevention, Guangzhou	19nCoV-CDC-Tan-GDPCC (B.1.351)
<b>Biological samples</b>		
Serum samples from BALB/c mice	This paper	N/A
Serum samples from hACE2 mice	This paper	N/A
Serum samples from rhesus macaques	This paper	N/A
Lung samples from hACE2 mice	This paper	N/A
Trachea samples from hACE2 mice	This paper	N/A
Serum samples from convalescent COVID-19 patients	Guangzhou 8th People's Hospital and Fifth Affiliated Hospital of Sun Yat-sen University	N/A
<b>Chemicals, peptides, and recombinant proteins</b>		
eBioscience Fixable Viability Dye eFluor 780	Invitrogen	Cat#65-0865
Isopropyl $\beta$ -D-1 thiogalactopyranoside (IPTG)	Takara	Cat#9030
Aluminium hydroxide gel	InvivoGen	Cat#vac-alu-250
Sigma adjuvant System (SAS)	Sigma-Aldrich	Cat#S6322
eBioscience Intracellular Fixation & Permeabilization Buffer Set	Invitrogen	Cat#88-8824

(Continued on next page)

REAGENT or RESOURCE	SOURCE	IDENTIFIER
eBioscience™ Brefeldin A Solution (1000X)	Thermo Scientific	Cat#00-4506-51
eBioscience™ Monensin Solution (1000X)	Thermo Scientific	Cat#00-4505-51
ELISA Stop Solution	Solarbio	C1058
eBioscience TMB Solution	eBioscience	Cat#00-4201
Carboxymethylcellulose sodium salt (CMC)	Sigma-Aldrich	21902; CAS9004-32-4
TrueBlue HRP Substrate	KPL	50-78-02
Paraformaldehyde	Sigma-Aldrich	P6148; CAS30525-89-4
Penicillin-Streptomycin, Liquid	ThermoFisher	Cat#15140122
Fetal Bovine Serum (FBS)	ThermoFisher	Cat#10270-106
SARS-CoV-2 Spike Glycoprotein Peptides Pool	GenScript	Cat#RP30020
synthetic B.1.351_RBD peptide (B.1.351_RBD 405-424 and B.1.351_RBD 495-514)	GenScript (This paper)	N/A
Recombinant Sd-Ferritin protein	This paper	N/A
Recombinant Gv-D614G_RBD	This paper	N/A
Recombinant Gv-B.1.351_RBD	This paper	N/A
<b>Critical commercial assays</b>		
RNeasy Mini Kit	QIAGEN	Cat#74104
SARS-CoV-2 RNA detection kit (PCR-Fluorescence Probing)	Da An Gene Co.	DA0931
Pierce Rapid Gold BCA Protein Assay Kit	ThermoFisher	Cat#A53225
Luciferase Assay System	Promega	Cat#E4550
<b>Experimental models: Cell lines</b>		
HEK293T	ATCC	CRL-3216; RRID: CVCL_0063
Vero E6	ATCC	CRL-1586; RRID: CVCL_0574
CHO-K1	ATCC	CCL-61
<b>Experimental models: Organisms/strains</b>		
BALB/c mice	Guangdong Medical Laboratory Animal Center	N/A
Transgenic hACE2 mice (C57BL/6)	GemPharmatech Co, Ltd	N/A
Rhesus macaques	Guangdong Landau Biotechnology Co, Ltd	N/A
<b>Oligonucleotides</b>		
SARS-CoV-2 nucleocapsid (N) qPCR Forward Primer: 5'-CAGTAGGGGAACCTTCTCCTGCT-3'	Da An Gene Co.	DA0931
SARS-CoV-2 nucleocapsid (N) qPCR Reverse Primer: 5'-CTTTGCTGCTGCTTGACAGA-3'	Da An Gene Co.	DA0931
SARS-CoV-2 nucleocapsid (N) Probe: 5'-FAM-CTGGCAATGGCGGTGATGCTGC-BHQ1-3'	Da An Gene Co.	DA0931
<b>Recombinant DNA</b>		
pET28a-Sd-Ferritin	This paper	N/A
pLVX-SP-Gv-D614G_RBD	This paper	N/A
pLVX-SP-Gv-B.1.351_RBD	This paper	N/A
psPAX2	Dr. Didier Trono	Addgene Plasmid #12260
pHIV-Luciferase	Dr. Bryan Welm	Addgene Plasmid #21375

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
SARS-CoV-2 (D614G) Spike Gene	This paper	hCoV-19/CHN/SYSU-IHV/2020 strain; GISAID: EPI_ISL_444969
SARS-CoV-2 (D614) Spike Gene	This paper	Wuhan-Hu-1; GISAID: EPI_ISL_402125
SARS-CoV-2 (B.1.1.7) Spike Gene	This paper	B.1.1.7 (GISAID: EPI_ISL_581117)
SARS-CoV-2 (B.1.351) Spike Gene	This paper	B.1.351 (GISAID: EPI_ISL_678597)
SARS-CoV-2 (P.1) Spike Gene	This paper	P.1 (GISAID: EPI_ISL_792683)
SARS-CoV-2 (B.1.429) Spike Gene	This paper	B.1.429 (GISAID: EPI_ISL_1675148)
SARS-CoV-2 (B.1.526) Spike Gene	This paper	B.1.526 (GISAID: EPI_ISL_1098596)
SARS-CoV-2 (B.1.617.1) Spike Gene	This paper	B.1.525 (GISAID: EPI_ISL_1093465)

**Software and algorithms**

GraphPad Prism v8.0 software	GraphPad	<a href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</a>
BD LSRFortessa cell analyzer	BD Biosciences	<a href="http://www.bdbiosciences.com/in/instruments/lsr/index.jsp">http://www.bdbiosciences.com/in/instruments/lsr/index.jsp</a>
FlowJo v10	Tree Star	<a href="https://www.flowjo.com/">https://www.flowjo.com/</a>
Image Studio Lite v4.0	LI-COR Biosciences	<a href="https://www.licor.com/bio/products/software/image_studio_lite/">https://www.licor.com/bio/products/software/image_studio_lite/</a>
QuantStudio 7 Flex System	ThermoFisher	<a href="https://www.thermofisher.com/order/catalog/product/4485701#/4485701">https://www.thermofisher.com/order/catalog/product/4485701#/4485701</a>
GloMax 96 Microplate Luminometer Software v1.9.3	Promega	<a href="https://www.promega.com/resources/software-firmware/detection-instruments-software/promega-branded-instruments/glomax-96-microplate-luminometer/">https://www.promega.com/resources/software-firmware/detection-instruments-software/promega-branded-instruments/glomax-96-microplate-luminometer/</a>
Skant SW for Microplate Readers	ThermoFisher	<a href="https://www.thermofisher.com/order/catalog/product/5187139?SID=srch-srp-5187139">https://www.thermofisher.com/order/catalog/product/5187139?SID=srch-srp-5187139</a>
ImmunoSpot software v5.1.34	Cellular Technology Ltd	<a href="http://www.immunospot.com/ImmunoSpot-analyzers">http://www.immunospot.com/ImmunoSpot-analyzers</a>

**Other**

Sepharose 6 FF	GE Healthcare	Cat#90100367
KR2i TangentialFlow Filtration system	Repligen	Cat#SYR2-U20
Capto SP ImpRes	GE Healthcare	Cat#17546815
Amicon Ultra-15 Centrifugal Filter Unit	Millipore	UFC900396
Olympus BX63	Olympus	<a href="https://www.olympus-lifescience.com.cn/zh/microscopes/upright/fluorescence/">https://www.olympus-lifescience.com.cn/zh/microscopes/upright/fluorescence/</a>

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Hui Zhang ([zhangh92@mail.sysu.edu.cn](mailto:zhangh92@mail.sysu.edu.cn)).

**Materials availability**

Plasmids sequences for vaccine components will be made available upon request. Purified proteins for *in vitro* experiments can be generated upon execution of a material transfer agreement (MTA) with inquiries directed to Dr. Hui Zhang.

**Data and code availability**

- All data supporting the findings of this study are available within the paper or from the corresponding author upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.



## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Ethics statements

The Ethics Review Board of Sun Yat-sen University approved this study. Animal experiments were carried out in compliance with the guidelines and regulations of the Laboratory Monitoring Committee of Guangdong Province of China. The animal experiments were also approved by the Ethics Committee of Zhongshan School of Medicine (ZSSOM) of Sun Yat-sen University on Laboratory Animal Care (Assurance Number: 2017-061). Authentic SARS-CoV-2 challenge studies were approved by the Ethics Committee of ZSSOM of Sun Yat-sen University on Laboratory Animal Care (Assurance Number: 2017-061) as well. Non-human primates experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Guangdong Landau Biotechnology Co, Ltd. (IACUC Approval No: LDACU 20200216-01). The Ethics Review Boards of Sun Yat-sen University, Guangzhou 8<sup>th</sup> People's Hospital and Fifth Affiliated Hospital of Sun Yat-sen University approved this study. Fifteen serum samples from convalescent COVID-19 patients were obtained from Guangzhou 8<sup>th</sup> People's Hospital and Fifth Affiliated Hospital of Sun Yat-sen University. All the convalescent sera were positive for RBD-specific antibodies (Liu et al., 2020).

### Cells and viruses

HEK293T, CHO-K1 and Vero E6 cells were obtained from ATCC. These adherent cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 1% penicillin-streptomycin (ThermoFisher) and 10% FBS (ThermoFisher). HEK293T expressing hACE2 (hACE2/HEK293T) was constructed in home. All cells were cultured in the sterile incubator at 37°C and 5% CO<sub>2</sub>. All cells have been confirmed to be mycoplasma free.

SARS-CoV-2 strains, named as hCoV-19/CHN/SYSU-IHV/2020 (D614G) (Accession ID on GISAID: EPI\_ISL\_444969) and 19nCoV-CDC-Tan-GDPCC (B.1.351) were propagated in Vero E6 cells as published before (Huang et al., 2021a; Ma et al., 2020). The D614G strain was isolated from the sputum of a female COVID-19 patient who was infected by a UK traveler in April 2020 by us, and the B.1.351 strain was isolated from a South Africa traveler by the Guangdong Center for Disease Control in January 2021. The sequence of this B.1.351 strain was performed by Guangdong Center for Disease Control and confirmed by us. The concentrations of D614G and B.1.351 were determined by FRNT as described below. All the authentic SARS-CoV-2-related experiments were conducted in the BSL-3 facility of Sun Yat-sen University.

### Animal models

Transgenic hACE2 mice (C57BL/6) were purchased from GemPharmatech Co, Ltd. The generation procedure was described as published before (Zhang et al., 2021d). Specific-pathogen-free (SPF) 5-6-week old female BALB/c mice were purchased from Guangdong Medical Laboratory Animal Center. All mice were housed and vaccinated in SPF facilities at the Laboratory Animal Center of Sun Yat-sen University. Four adult rhesus macaques (2 male and 2 female) between 2-4-year old were purchased from Guangdong Landau Biotechnology Co, Ltd. Monkeys experiments were conducted according to the guidelines and regulations of the Laboratory Monitoring Committee of Guangdong Province of China.

## METHOD DETAILS

### Protein expression and purification

The RBD nanoparticle vaccine was constructed as described previously (Ma et al., 2020). To further improve the conjugation efficiency of the NP vaccine, we screened and modified a variety of natural CnaB2 proteins with isopeptide bonds from various bacterial strains. Additionally, we optimized the conjugation efficiency by generating several mutants based upon the structural prediction. Finally, we identified a potent combination of GvTagOpti (Gv) and SdCatcher (Sd) from *Gardnerella vaginalis* and *Streptococcus dysgalactiae* respectively, which significantly enhanced the assemble efficiency and the production of the SARS-CoV-2 NP vaccine (Zhang et al., 2021c). The Sd-Ferritin was expressed and purified from *Escherichia coli* (E.coli). Briefly, the Sd was genetically fused at the N terminus of Ferritin (Sd-Ferritin), DNA sequences of Sd-Ferritin were cloned to the pET28a vector. The construct was transformed into BL21 (Takara). A single clone was amplified in LB with kanamycin while shaking at 37°C. The isopropyl b-D-1 thiogalactopyranoside (IPTG) (Takara) was added to the bacterial solution to induce protein expression. Eighteen hours after induction, the bacteria expressing the protein were harvested and lysed by sonication. After centrifugation, the supernatants were loaded onto a Sepharose 6 FF (GE Healthcare) size exclusion column that was pre-equilibrated with 20 mM Tris 50 mM NaCl buffer (pH 7.5) and eluted with the same buffer at a rate of 10 mL min<sup>-1</sup>. The total volume of the column (V<sub>t</sub>) was 53 mL, and the elution volume (V<sub>e</sub>) of Sd-ferritin NP was 26 mL. The concentration of Sd-Ferritin was determined by BCA assay. The bacterial endotoxins in nanoparticles were quantified by the Tachypleus amebocyte lysate test ( $\leq 10$  EU/dose). Coomassie blue staining, size-exclusion chromatography (SEC), and transmission electron microscopy (TEM) were executed to confirm the purity and homogeneity (Wang et al., 2020b).

The D614G\_RBD and B.1.351\_RBD were expressed and purified from Chinese hamster ovary K (CHO-K1) cells. Briefly, The Gv coding sequence was fused at the N-terminus of the D614G\_RBD or B.1.351\_RBD sequence. DNA sequences of SP-Gv-D614G\_RBD and SP-Gv-B.1.351\_RBD were codon-optimized for mammalian cell expression and cloned into vector plasmid pLVX. The constructed pLVX, lentiviral packaging plasmids psPAX2, and pLP/VSF were transfected into HEK293T cells cultured

in DMEM conditioned medium. Lentiviruses released in the supernatant were collected 60 h after transfection and then infected anchorage-dependent CHO-K1 cells cultured in F12K medium. The supernatant was removed 8 h later and changed with new a F12K medium for another day of culture. The F12K medium was then replaced with CHO S4 medium, which was used for cell suspension and expansion to a density of  $3 \times 10^6$  cells/mL. Seven days later, supernatants were collected and centrifuged to discard cellular debris. The cleared supernatants were passed through the KR2i TangentialFlow Filtration system equipped with filters (Repligen) with 10-kDa and 100-kDa molecular weight cutoffs (MWCO) to obtain the 10–100kDa molecular weight proteins. The concentrates were purified by AKTA pure system using Capto SP Impres (GE Healthcare) columns running phosphate-buffered (PH= 7) and eluted with the 150 mM NaCl phosphate-buffered (PH= 7) buffer at a rate of  $5 \text{ mL min}^{-1}$ . The purified proteins were concentrated and buffer-replaced with conventional Tris buffer. The concentrations of D614G\_RBD and B.1.351\_RBD were determined by BCA assay. Coomassie blue staining was executed to confirm the purity.

The purified Gv-D614G\_RBD and Gv-B.1.351\_RBD were irreversibly covalently conjugated to the Sd-Ferritin to generate the D614G\_RBD-nanoparticle (NP) and B.1.351\_RBD-NP. The bivalent D614G/B.1.351\_RBD-NP vaccine comprises a 1:1 mix of D614G\_RBD-NP and B.1.351\_RBD-NP.

### Surface plasmon resonance (SPR)

The measurements of Ferritin, D614G\_RBD, B.1.351\_RBD, D614G\_RBD-NP, and B.1.351\_RBD-NP binding to hACE2 were carried out with a BIAcore T100 instrument (GE Healthcare). A BIAcore CM5 Sensor Chip and an amine coupling kit were purchased from GE Healthcare. hACE2 was immobilized on a CM5 Sensor Chip (carboxymethylated dextran covalently attached to a gold surface) with the amine coupling kit (GE Healthcare). Ferritin, D614G\_RBD-NP, and B.1.351\_RBD-NP were diluted into different concentrations and then injected ( $30 \text{ mL min}^{-1}$ ). hACE2-bound protein was monitored for about 120 s for each protein. The dissociation time was 200 s with running buffer per cycle. The signals were recorded by the Biacore T100 instrument with the standard protocols.

### Size-exclusion chromatography (SEC)

Gv-D614G\_RBD and Gv-B.1.351\_RBD were incubated with Sd-Ferritin in the Tris-HCl buffer. After 8 h, the bound protein was subjected to Size-Exclusion Chromatography (SEC). D614G\_RBD-NP and B.1.351\_RBD-NP were eluted in retention of retaining 11 mL to 14 mL. The elution of nanoparticles was concentrated, and the concentration was measured by BCA assay. Coomassie blue staining, size-exclusion chromatography (SEC), and transmission electron microscopy (TEM) were executed to confirm the purity and homogeneity (Ma et al., 2020).

### Transmission electron microscopy (TEM)

Transmission electron microscopy (TEM) Grids of SD-Ferritin, D614G\_RBD-NP, and B.1.351\_RBD-NP have proceeded to negative-stain electron microscopy in Shuimu BioSciences Ltd. Briefly, the Talos L120C (ThermoFisher) was operated at an accelerating voltage 120 kV to collect data on the sample. Samples were inspected with magnifications of 36 kx and 57 kx, respectively, with a pixel size of 0.245 nm and an electron dose of  $15 \text{ e}^-/\text{A}^2$ , and a total of 164 data were collected. Using cisTEM software to process the collected data, 45244 particles were picked out, and two-dimensional classification was performed with EMAN2.

### Animal vaccination

For BALB/c mice vaccination, five BALB/c mice were subcutaneously immunized with  $10 \mu\text{g}$  of D614G/B.1.351\_RBD-NP formulated with Alum (InvivoGen) adjuvant. Mice in D614G\_RBD-NP and B.1.351\_RBD-NP groups were immunized with equal moles of D614G\_RBD-NP and B.1.351\_RBD-NP. The moles of D614G/B.1.351 RBD in the monomers group were the same as D614G\_RBD-NP and B.1.351\_RBD-NP in the D614G/B.1.351\_RBD-NP group, respectively. Mice in the Ferritin group were immunized with equal moles of ferritin, which were the same as the D614G/B.1.351\_RBD-NP group. All the mice were vaccinated with the above vaccines in a prime/boost manner, which vaccinated mice at week 0 and week 4. Serum was collected every two weeks. Mice were euthanized at week 6.

For hACE2 mice vaccination, for prime-boost strategy, all the mice were vaccinated as in BALB/c mice. Mice were challenged with authentic SARS-CoV-2 four weeks post-boost vaccination and euthanized 5 days post-challenge. Serum was collected at weeks 0, 2, 6, and 8. For single-dose strategy, mice were subcutaneously immunized with  $2 \mu\text{g}$ ,  $5 \mu\text{g}$ , and  $10 \mu\text{g}$  of vaccine formulated with Alum (InvivoGen) adjuvant. Mice were challenged with authentic SARS-CoV-2 six weeks post-vaccination and euthanized 5 days post-challenge. Serum was collected at weeks 0, 2, and 6.

For rhesus macaques vaccination, four monkeys were immunized with  $50 \mu\text{g}$  of D614G\_RBD-NP vaccine via intramuscular injection in a prime/boost manner, which was vaccinated at week 0 and week 4. Sera from monkeys were collected every two weeks. On Day 282, four monkeys were immunized with  $50 \mu\text{g}$  of D614G/B.1.351\_RBD-NP vaccine. Serum was collected every two weeks after the third dose immunization. All vaccines were formulated with Sigma Adjuvant System (SAS) adjuvant.

### Quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Different tissues of each mouse, including lung and trachea, were collected and homogenized with gentleMACS M tubes (Miltenyi Biotec, 130-093-236) in a gentleMACS dissociator (Miltenyi Biotec, 130-093-235). RNAs of homogenized tissues were extracted with RNeasy Mini Kit (QIAGEN,74104) according to the manufacturer's instruction, followed by qRT-PCR to determine viral RNA

copies of different tissues utilizing a one-step SARS-CoV-2 RNA detection kit (PCR-Fluorescence Probing) (Da An Gene Co., DA0931). The SARS-CoV-2 nucleocapsid (N) gene was cloned into a pcDNA3.1 expression plasmid and *in vitro* transcribed to obtain RNAs as standards to generate a standard curve. The indicating copies of N standards were 10-fold serially diluted and proceeded with qRT-PCR utilizing the same one-step SARS-CoV-2 RNA detection kit to obtain standard curves. The reactions were carried out in a QuantStudio 7 Flex System (Applied Biosystems). The N-specific primers, probes and reaction conditions were the same as published before (Li et al., 2021a). The viral RNA copies of each tissue were calculated into copies per mL and presented as a log<sub>10</sub> scale. In each qRT-PCR experiment, both positive control and negative control of simulated RNA virus particles were included to monitor the entire experimental process and ensure the reliability of the test results.

### Enzyme linked immunosorbent assay (ELISA)

Recombinant D614G\_RBD and B.1.351\_RBD protein was diluted to a concentration of 2 μg/mL concentration in coating buffer to coat on high-binding 96-well plates (Corning) respectively, overnight at 4 °C. After washed three times with PBS, the plates were blocked with 5% non-fat milk/PBS for 1 h. After another round of washing, the immunized animal serum was serially diluted and added into each well in duplicate, followed by incubating at room temperature for 1 h. The detection of antigen-specific IgG antibody in serum of BALB/c mice, hACE2 mice, or rhesus macaques was conducted through adding HRP-conjugated goat anti-mouse or goat anti-monkey secondary antibody (Invitrogen) respectively at dilution of 1:10000, and incubating for another 1 h after washing with PBS/T (containing 1% Tween-20) three times. The plates were washed four times before 100 μL TMB solution (eBioscience) was added to each well. After 5 min of chromogenic progress at room temperature, 100 μL stop solution (Solarbio) was added to quench reaction followed by absorption measure at 450 nm. The IgA antibodies in BALF of BALB/c mice were measured similarly using an HRP-conjugated polyclonal goat anti-mouse IgA antibody (1:10000 diluted in PBS; Immunoway). The data were analyzed using GraphPad Prism 8.0 software for non-linear regression to calculate endpoint titers.

### SARS-CoV-2 infection

Specific-pathogen-free (SPF), transgenic hACE2 mice (C57BL/6), which have been immunized with different vaccines, were challenged with authentic SARS-CoV-2 in the BSL-3 facility (Zhang et al., 2021a; Zhang et al., 2021d). Littermates of the same sex were randomly assigned to un-infection or infection groups. D614G and B.1.351 were used to challenge mice. Mice were anesthetized with isoflurane and inoculated intranasally with 4×10<sup>4</sup> FFU (Focus-forming unit) of SARS-CoV-2 viruses. The lungs were collected at 5 days post-infection (d.p.i.). The virus stocks were obtained from the supernatant of Vero E6 after inoculation for 48 h, and the titers were determined by FRNT assay targeting nucleocapsid (N) protein.

### Histopathology and immunohistochemistry

SARS-CoV-2-challenged hACE2 mice were euthanized in the BSL-3 facility. Lungs were collected and fixed in 4% paraformaldehyde buffer for 48 h, followed by embedding with paraffin. Longitudinal sections were performed on these tissues. The sections (3–4 μm) were stained with hematoxylin and eosin (H&E). For immunohistochemistry, lung sections of each mouse were incubated with rabbit anti-SARS-CoV-2 Nucleoprotein (N) at 1:200 dilution and the IHC were conducted as published before (Zhang et al., 2021d).

### Focus reduction neutralizing test (FRNT)

The method was consistent as described previously (Li et al., 2021c; Ma et al., 2020). Briefly, the Vero E6 cells were seeded in 96-well plates at a density of 2×10<sup>4</sup> cells per well and incubated the plates until cells reached 90–100% confluent. The serum of BALB/c mice, hACE2 mice, and rhesus macaques at each time point was 10-fold serially diluted. Five hundred FFU of authentic SARS-CoV-2 viruses were mixed with the diluted serum in a ratio of 1:1 for 1 h incubation at 37°C. Cell culture medium was removed from the 96-well plate, followed by the incubating with virus/serum mixture. Plates were then incubated for 1 h at 37°C. The DMEM containing 1.6% CMC was added to each well incubated for 24 hours after the supernatant was removed. On the next day, released the supernatant and cells were fixed with 200 μl of 4% paraformaldehyde in each well. After further incubation at 4°C for 12 h, removed the fixative, and plates were washed with 200 μl PBS each well for 3 times. And then, 100 μl PBS containing 0.2% Triton X-100 and 1% BSA was added to each well. After reaction for 30 mins at room temperature, each well was washed with 200 μl PBS for 3 times and incubated 50 μl of the diluted primary antibody (Anti-SARS-N; 40143-T62-100), which was diluted to 1:1000 with PBS solution containing 1% BSA at 37°C for 1 h. After primary antibody incubation, the cell within each well was washed 3 times with 200 μl PBS/T (0.1% Tween). The secondary antibody (Goat anti-rabbit IgG HRP; SSA004-1) was diluted to 1:2000 with PBS solution containing 1% BSA. 50 μl of the diluted secondary antibody was added to each well and incubated at 37°C for 1 h, followed by washing with PBS/T three times. 50 μl TrueBlue (KPL) was added to each well and set for 5 mins shaking at room temperature. Plates were washed with ddH<sub>2</sub>O, and the liquid was eradicated, followed by spot counting using with ImmunoSpot Microanalyzer. The reduction rates of the serial dilution assay were analyzed by GraphPad Prism 8.0 using non-linear regression to measure the FRNT50 titer (Zhang et al., 2021b).

### Pseudotyped virus neutralization assay

Briefly, HEK293T cells were co-transfected with packaging plasmid psPAX2, luciferase-expressing lentivirus plasmid, and respective variant spike protein-expressing plasmid using polyethyleneimine (PEI, Sigma). Forty-eight hours after transfection, culture supernatants were collected, clarified of cells before stored in -80°C. Virus titration was performed by serial-diluted virus infection on hACE2

cells, and infectivity was measured by detection of luminescence, details would be shown as follows. All the convalescent serum and immunized animal serum were serially diluted and incubated with pre-titrated amounts of SARS-CoV-2 pseudotyped virus at 37°C for 1 h. Then the serum/virus mixture was then added into wells containing  $1 \times 10^4$  hACE2 cells and incubated at 37°C in 5% CO<sub>2</sub> for 48 h. Cells were then lysed with lysis buffer (Promega), and the lysate was the measure for luciferase activity by detecting relative luminescence units (RLU) in a luminometer (Promega). Neutralizing antibody titers of serum against the pseudotyped virus were analyzed using GraphPad Prism 8.0 software (Zhang et al., 2021d).

### Intracellular cytokine staining (ICCS)

The spleen was collected in PBS, homogenized through a 70  $\mu$ m strainer and incubated in ACK lysis buffer to remove red blood cells (RBCs), followed by passing through a 40  $\mu$ m filter to obtain single splenocytes. To quantify the percentages of antigen-specific T cells, approximately 1 million splenocytes were seeded into each well and stimulated with peptides pool, which consists of SARS-CoV-2 Spike Glycoprotein peptides pool (GenScript) and two synthetic B.1.351\_RBD peptide (B.1.351\_RBD 405-424 and B.1.351\_RBD 495-514). Each peptide was used at a final concentration of 2  $\mu$ g/mL. Cells were co-stimulated with 2  $\mu$ g/mL anti-CD28 (Biolegend) at 37°C with 5% CO<sub>2</sub> for 1 h. Cells were then incubated with 5  $\mu$ g/mL brefeldin A (Thermo Scientific) and 2  $\mu$ M monensin (Thermo Scientific). DMSO was used as a negative control. PMA/ionomycin was used as a positive control. After a total of 6 h, the LIVE/DEAD Fixable Viability Dyes (Thermo Scientific) were used to exclude dead cells from analysis (Zhang et al., 2021e). Subsequently, cells were performed with a fixation/permeabilization kit (BD Biosciences). The following cytokine antibodies were used: anti-IFN- $\gamma$  (XMG1.2), anti-IL-2 (JES6-5H4), and anti-IL-4 (11B11). The percentages of cytokine-specific splenocytes were analyzed by flow cytometry.

### QUANTIFICATION AND STATISTICAL ANALYSIS

All the statistical details of specific experiments, which included the statistical tests used, number of samples, mean values, standard errors of the mean (SD), and p-values derived from indicated tests, had been described in the figure legends and showed in figures. Statistical analyses were conducted utilizing Graphpad Prism 8.0 or Microsoft Excel. Triplicate, sextuplicate, and other replicative data were presented as mean  $\pm$  SD. Value of  $p < 0.05$  was considered to be statistically significant and represented as an asterisk (\*). Value of  $p < 0.01$  was supposed to be more statistically significant and described as double asterisks (\*\*). Value of  $p < 0.001$  was considered the most statistically significant and represented as triple asterisks (\*\*\*). Value of  $p < 0.0001$  was supposed to be extremely statistically substantial and described as quadruple asterisks (\*\*\*\*). For comparison between two treatments, a Student's t-test was used. For comparison between each group with the mean of every other group within a dataset containing more than two groups, one-way ANOVA with Tukey's multiple comparisons test was used.